Intravitreal dexamethasone implants for diabetic macular edema.

Aim: To evaluate the safety and efficacy of a dexamethasone (DEX) intravitreal implant for diabetic macular edema (DME).

Methods: Totally 113 eyes of 84 patients were divided in three subgroups: naive patients (=11), pseudophakic patients (=72) and phakic patients (=30). Inclusive criterion comprised adult diabetic patients with central fovea thickening and impaired visual acuity resulting from DME for whom previous standard treatments showed no improvement in both central macular thickness (CMT) and best corrected visual acuity (BCVA) after at least 3mo of treatment.